Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

DBCOND0081226Neoplasms

Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma is the indication for 1 drug in DrugBank. It is covered by 1 curated, structured indication.

Also known as: Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck · Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck · Metastatic or Recurrent HNSCC · Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck · recurrent, metastatic Head and Neck Squamous Cell Carcinoma
Classified under: Neoplasms
Indicated drugs: Nivolumab

What you can answer from here — as of October 22, 2026

1Indicated drugWith each drug's targets and mechanism

Listed above

1Structured indicationPopulation, line of therapy, route and combination as fields, not prose

22Clinical trialsPhase, status and sponsor resolved per trial

2Drugs reporting it as an adverse effectWith incidence where the label states it

Which approved drugs for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account